You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 111 No. 4, April 1975 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (42)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Tar Phototoxicity and Phototherapy for Psoriasis

Lewis Tanenbaum, MD; John A. Parrish, MD; Madhu A. Pathak, MB, PhD; R. Rox Anderson; Thomas B. Fitzpatrick, MD, PhD

Arch Dermatol. 1975;111(4):467-470.


Abstract

The phototoxicity of coal tars was determined by comparing the ultraviolet light (UVL) energy required to produce erythema at tar treated sites (minimal phototoxic dose [MPD]) with the energy required to produce the same degree of erythema at untreated control sites (minimal erythema dose [MED]). The ratio of MED/MPD is the phototoxic index (PI). Tars that were phototoxic had a PI of > 1. Using a UVA (320 to 400 nm) and a UVB (290 to 320 nm) light source, 15 subjects and six tars were tested. All tars were phototoxic to UVA but not to UVB (P < 0.0001).

Although tar and UVL is a widely accepted treatment for psoriasis (Goeckerman therapy), the light sources employed at normal exposure times provide insufficient UVA energy to produce a phototoxic reaction to the tars that are used. The therapeutic response seen in psoriatic patients treated with tar and UVL should therefore not be attributed to tar phototoxicity.



Author Affiliations

From the Department of Dermatology, Harvard Medical School and Massachusetts General Hospital, Boston.


Footnotes

Accepted for publication Sept 16, 1974.

Reprint requests to Department of Dermatology, Massachusetts General Hospital, Fruit St, Boston, MA 02114 (Dr. Tanenbaum).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Narrowband UV-B and Psoriasis
Stern
Arch Dermatol 1997;133:1587-1588.
ABSTRACT  

UV-B Phototherapy: An Overview
Anderson et al.
Arch Dermatol 1984;120:1502-1507.
ABSTRACT  

Quinidine Photosensitivity
Marx et al.
Arch Dermatol 1983;119:39-43.
ABSTRACT  

Actinic Reticuloid
Marx et al.
Arch Dermatol 1982;118:672-675.
ABSTRACT  

The Role of Tar in Goeckerman Therapy
Belsito and Kechijian
Arch Dermatol 1982;118:319-321.
ABSTRACT  

Outpatient Phototherapy of Psoriasis
LeVine and Parrish
Arch Dermatol 1980;116:552-554.
ABSTRACT  

Tar Gel-Phototherapy for Psoriasis: Combined Therapy With Suberythemogenic Doses of Fluorescent Sunlamp Ultraviolet Radiation
Frost et al.
Arch Dermatol 1979;115:840-846.
ABSTRACT  

Phototoxicity to a Sunscreen Ingredient: Padimate A
Kaidbey and Kligman
Arch Dermatol 1978;114:547-549.
ABSTRACT  

Treatment of Psoriasis With Long-Wave Ultraviolet Light
Parrish
Arch Dermatol 1977;113:1525-1528.
ABSTRACT  

Ultraviolet Light and Tar in the Goeckerman Treatment of Psoriasis
Marsico et al.
Arch Dermatol 1976;112:1249-1250.
ABSTRACT  

Therapy With Keratolytic Gel and Corticosteroid Ointment
Baden
Arch Dermatol 1975;111:1536-1536.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1975 American Medical Association. All Rights Reserved.